Health Tech Capitol | Arrowhead Pharmaceuticals makes $267 million public stock offering
16909
post-template-default,single,single-post,postid-16909,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Arrowhead Pharmaceuticals makes $267 million public stock offering

08 Dec Arrowhead Pharmaceuticals makes $267 million public stock offering

Posted at 11:35h in Uncategorized by
0 Likes

$267 million stock offering last week by Arrowhead Pharmaceuticals, which has its main employment base in Madison, could help the company bring experimental drugs to market and lead to the purchase of other businesses.

The offering of 4.6 million shares of stock at $58 per share, announced Monday and closed Friday, was estimated at $267 million in gross proceeds, or $250 million after deducting underwriting discounts, commissions and other expenses.

Arrowhead — based in Pasadena, California — has 110 of its 150 employees at University Research Park on Madison’s West Side.

Read more at the Wisconsin State Journal

No Comments

Sorry, the comment form is closed at this time.